These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28858725)

  • 1. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
    Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
    Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
    Nishimura Y; Martin MA
    Cell Host Microbe; 2017 Aug; 22(2):207-216. PubMed ID: 28799906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Gruell H; Klein F
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():46-9. PubMed ID: 26048121
    [No Abstract]   [Full Text] [Related]  

  • 7. Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV.
    Ghofrani J; Bowen A; Chen J; Balakrishnan PB; Powell AB; Cherukula K; Cruz CRY; Jones RB; Lynch RM; Sweeney EE; Fernandes R
    Int J Nanomedicine; 2023; 18():4055-4066. PubMed ID: 37520301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
    Lin A; Balazs AB
    Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
    Klein F; Nogueira L; Nishimura Y; Phad G; West AP; Halper-Stromberg A; Horwitz JA; Gazumyan A; Liu C; Eisenreich TR; Lehmann C; Fätkenheuer G; Williams C; Shingai M; Martin MA; Bjorkman PJ; Seaman MS; Zolla-Pazner S; Karlsson Hedestam GB; Nussenzweig MC
    J Exp Med; 2014 Nov; 211(12):2361-72. PubMed ID: 25385756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
    Paneerselvam N; Khan A; Lawson BR
    Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of broadly neutralizing antibodies for HIV-1 prevention.
    Pegu A; Hessell AJ; Mascola JR; Haigwood NL
    Immunol Rev; 2017 Jan; 275(1):296-312. PubMed ID: 28133803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Immune Interventions for an HIV-1 Cure.
    Perreau M; Banga R; Pantaleo G
    Trends Mol Med; 2017 Oct; 23(10):945-961. PubMed ID: 28890135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing antibodies: An approach to control HIV-1 infection.
    Yaseen MM; Yaseen MM; Alqudah MA
    Int Rev Immunol; 2017 Jan; 36(1):31-40. PubMed ID: 27739924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Interventions in HIV Cure Research.
    Rasmussen TA; Søgaard OS
    Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
    Mendoza P; Gruell H; Nogueira L; Pai JA; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Lorenzi JCC; Cohen YZ; Wyen C; Kümmerle T; Karagounis T; Lu CL; Handl L; Unson-O'Brien C; Patel R; Ruping C; Schlotz M; Witmer-Pack M; Shimeliovich I; Kremer G; Thomas E; Seaton KE; Horowitz J; West AP; Bjorkman PJ; Tomaras GD; Gulick RM; Pfeifer N; Fätkenheuer G; Seaman MS; Klein F; Caskey M; Nussenzweig MC
    Nature; 2018 Sep; 561(7724):479-484. PubMed ID: 30258136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons.
    Tebas P; Lynn K; Azzoni L; Cocchella G; Papasavvas E; Fair M; Karanam B; Sharma P; Reeves JD; Petropoulos CJ; Lalley-Chareczko L; Kostman JR; Short W; Mounzer K; Montaner LJ
    AIDS; 2023 Jul; 37(8):1203-1207. PubMed ID: 37070542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality.
    Waters L; de Miguel-Buckley R; Poulin S; Arribas JR
    Clin Infect Dis; 2023 Mar; 76(6):1136-1141. PubMed ID: 36303321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.